Moreover, immunotherapies such as interleukin-2 (IL-2), adoptive cell transfer, and antibodies targeting cytotoxic T-lymphocyte–associated antigen 4 or programmed death 1 receptor (PD-1) seem promising for treating cancers [7]. Here, PDCD1 is linked to cancer.